Abstract
The explosive emergence of Zika virus has inspired a global effort to develop vaccines. Zika virus, which is a flavivirus primarily transmitted by mosquitoes, can cause devastating congenital syndrome in fetuses of pregnant women, including microcephaly, craniofacial disproportion, spasticity, ocular abnormalities, and miscarriage. In adults, Zika infection has been linked to the autoimmune disorder Guillain-Barré syndrome. Thus, despite the current waning in newly reported Zika infections, an efficacious vaccine is urgently needed to help limit the emergence of another detrimental epidemic. Here we summarize the current status of the Zika vaccine pipeline and highlight the challenges for clinical efficacy trials. Shan et al. review the current status of the Zika virus vaccine pipeline, highlight the challenges for efficacy trial in humans, underline the knowledge gaps required for clinical development, and provide potential solutions to overcome the barriers toward licensure.
| Original language | English (US) |
|---|---|
| Journal | Cell Host and Microbe |
| DOIs | |
| State | Accepted/In press - Jan 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Parasitology
- Microbiology
- Virology
Cite this
Zika Virus Vaccine : Progress and Challenges. / Shan, Chao; Xie, Xuping; Shi, Pei-Yong.
In: Cell Host and Microbe, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Zika Virus Vaccine
T2 - Progress and Challenges
AU - Shan, Chao
AU - Xie, Xuping
AU - Shi, Pei-Yong
PY - 2018/1/1
Y1 - 2018/1/1
N2 - The explosive emergence of Zika virus has inspired a global effort to develop vaccines. Zika virus, which is a flavivirus primarily transmitted by mosquitoes, can cause devastating congenital syndrome in fetuses of pregnant women, including microcephaly, craniofacial disproportion, spasticity, ocular abnormalities, and miscarriage. In adults, Zika infection has been linked to the autoimmune disorder Guillain-Barré syndrome. Thus, despite the current waning in newly reported Zika infections, an efficacious vaccine is urgently needed to help limit the emergence of another detrimental epidemic. Here we summarize the current status of the Zika vaccine pipeline and highlight the challenges for clinical efficacy trials. Shan et al. review the current status of the Zika virus vaccine pipeline, highlight the challenges for efficacy trial in humans, underline the knowledge gaps required for clinical development, and provide potential solutions to overcome the barriers toward licensure.
AB - The explosive emergence of Zika virus has inspired a global effort to develop vaccines. Zika virus, which is a flavivirus primarily transmitted by mosquitoes, can cause devastating congenital syndrome in fetuses of pregnant women, including microcephaly, craniofacial disproportion, spasticity, ocular abnormalities, and miscarriage. In adults, Zika infection has been linked to the autoimmune disorder Guillain-Barré syndrome. Thus, despite the current waning in newly reported Zika infections, an efficacious vaccine is urgently needed to help limit the emergence of another detrimental epidemic. Here we summarize the current status of the Zika vaccine pipeline and highlight the challenges for clinical efficacy trials. Shan et al. review the current status of the Zika virus vaccine pipeline, highlight the challenges for efficacy trial in humans, underline the knowledge gaps required for clinical development, and provide potential solutions to overcome the barriers toward licensure.
UR - http://www.scopus.com/inward/record.url?scp=85048570657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048570657&partnerID=8YFLogxK
U2 - 10.1016/j.chom.2018.05.021
DO - 10.1016/j.chom.2018.05.021
M3 - Article
C2 - 30008291
AN - SCOPUS:85048570657
JO - Cell Host and Microbe
JF - Cell Host and Microbe
SN - 1931-3128
ER -